USPTO serial 86680061
Q2 SOLUTIONS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 25, 2017
- Examiner
- MAYES, LAURIE ANN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This registration is in, or will soon enter, a USPTO maintenance window. Missing a Section 8 or Section 9 filing can cancel the registration.
Need help with Q2 SOLUTIONS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Get help with this Renewal, set up monitoring, or talk with CopyMark.
Get Attorney Assistance for just $1,446*
Plus Government fees of $2,600
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Q Squared Solutions Holdings LLC
Morrisville, NC, US
Q Squared Solutions Holdings LLC
Morrisville, NC, US
Q Squared Solutions Holdings LLC
Durham, NC, US
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Arlene D. Hanks
Arlene D. Hanks Moore & Van Allen PLLC100 North Tryon StreetSuite 4700Charlotte, NC 28202-4003Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | [ Computer software for providing, managing and analyzing laboratory clinical trial data and laboratory and clinical trials information in the fields of pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, medical, health care, health management and disease management fields; computer software that allows remote access to clinical trial laboratory data and laboratory and clinical trials information; computer software for use in collecting and reporting medical data relating to patient medical conditions for clinical trials, research, peri- and post-approval studies, quality improvement, and patient support programs; none of the foregoing for use in the field of Medicare ] | SECTION 8 - CANCELLED | Jul 2, 2015 |
| 035 | Computerized database management and data processing services in the pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics fields; providing business information, namely, information related to regulatory approval and marketing of drugs, devices, health care or medical products and services, and biologics; business research in the field of health care; business consultation in the field of healthcare; business technology consulting, namely, business consulting services relating to the integration of the areas of business process technology, change management and operational sustainability in the healthcare, medical, health management and disease management fields; none of the foregoing for use in the field of Medicare | ACTIVE | Jul 2, 2015 |
| 041 | [ Educational and training services, namely, conducting training programs, seminars, classes, conferences and workshops in the fields of health policy, health management, and disease management, patient management, and pharmaceutical, pharmacogenomic, biomarker, medical device and diagnostics, and distributing course materials in connection therewith; teaching and training in information technology for the healthcare industry; all of the foregoing relating to clinical trials, clinical research, medical and scientific laboratory services, biopharmaceutical, biomarker, diagnostics and medical product and device development, and research, testing, regulatory approval and commercialization of diagnostics, biopharmaceuticals, biomarkers and medical products and devices and none of the foregoing for use in the field of or related to Medicare or other governmental health programs ] | SECTION 8 - CANCELLED | Jul 2, 2015 |
| 042 | Clinical research and testing services, in the fields of clinical trials, health care products, pharmaceutical products, pharmacogenomics products, biomarker products, biopharmaceutical products, medical devices and diagnostics products; product development consultation in the fields of health care, medical products and devices; health care research and product development services; medical and laboratory testing services for research purposes; laboratory testing services for research purposes in the fields of health care, clinical trials, pharmaceutical, pharmacogenomics, biomarker, biopharmaceutical, medical device and diagnostics; consultancy in the design, planning and implementation project management of clinical trials; health care medical research consultancy; product development consultancy in the fields of medical diagnostics, medical devices, pharmacology, pharmacogenomics, biomarkers and biopharmaceutical research; managing, namely, monitoring, coordinating and implementing clinical studies being clinical trials on human subjects for others for research purposes; medical and scientific research in the fields of healthcare and medical diagnostics; providing temporary use of non-downloadable, web-based software application for providing access to information and data in the clinical trials, pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields and for organizing and analyzing said data and information and preparing reports therefrom, providing temporary use of non-downloadable software for providing, managing and analyzing laboratory clinical trial data and information in the fields of pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, medical device and diagnostics, life sciences, health management and disease management fields; providing temporary use of non-downloadable software that allows remote access to clinical trial peri- and post-approval laboratory data and information; providing temporary use of non-downloadable software for use in collecting and reporting medical data relating to patient medical conditions for research; providing scientific and medical research information relating to the development and validation of drugs, pharmaceutical products, medical products, medical devices and biologics; providing an internet website portal featuring scientific and medical research information in the fields of clinical trials, pharmaceutical research, pharmacogenomic and biomarker consultation, biopharmaceutical consultation, medical devices and diagnostics, life sciences research, and medical research; providing an online searchable database via the internet featuring medical and scientific research information in the fields of clinical trials, companion diagnostics, pharmaceutical research, pharmacogenomic and biomarkers, biopharmaceuticals, medical devices and diagnostics, life sciences research, and medical research; all of the foregoing relating to clinical trials, clinical research, medical and scientific laboratory services, biopharmaceutical, biomarker, diagnostics and medical product and device development, and research, testing, regulatory approval and commercialization of diagnostics, biopharmaceuticals, biomarkers and medical products and devices and none of the foregoing for use in the field of or related to Medicare or other governmental health programs | ACTIVE | Jul 2, 2015 |
| 044 | Providing health and medical information; providing pharmaceutical information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; providing medical information relating to pharmacogenomics and biomarkers; health management and disease management medical information to others; medical evaluation services; medical consulting services in the fields of health care, medicine, life sciences, and pharmaceuticals, biopharmaceuticals, biomarkers, pharmacogenomics, medical device and diagnostics; providing an online interactive computer database in the field of healthcare featuring healthcare information; providing an Internet website portal featuring medical and healthcare information in the fields of medical services, health care, health management and disease management; providing an online searchable database via the internet featuring medical and healthcare information in the fields of medical services, medical devices and diagnostics, health care, health management and disease management; none of the foregoing for use in the field of Medicare | ACTIVE | Jul 2, 2015 |
| 045 | Regulatory compliance research and consulting services in the fields of health care, clinical trials, development and testing of drugs, devices, biologics and methodologies used in the pharmaceutical industry, biotechnology industry and the medical device and diagnostics industry; conducting regulatory compliance audits for others in the fields of health care, clinical trials, pharmaceutical, pharmacogenomic, biomarker, biopharmaceutical, and medical device and diagnostics; consulting services in the fields of regulatory affairs, namely, regulatory compliance consulting in the field of prescription drug sampling; manufacturing compliance and validation procedures, namely, reviewing standards and practices to assure compliance with clinical trial regulations, medical and laboratory testing services; providing regulatory information, namely, providing regulatory compliance information regarding the examination and approval process of pharmaceutical, biotechnical, medical and diagnostic products and methodologies by governmental regulatory bodies; providing regulatory compliance consulting services relating to the development and validation of drugs, devices and biologics, namely, assisting others in implementing procedures that comply with regulatory requirements; none of the foregoing for use in the field of Medicare | ACTIVE | Jul 2, 2015 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks owned by Q Squared Solutions Holdings LLC
- Other trademarks in Class 009
- Other trademarks in Class 035
- Other trademarks in Class 041
- Other trademarks in Class 042
- Other trademarks in Class 044
- Other trademarks in Class 045
- Similar marks named Q2 SOLUTIONS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 25, 2026 | REM2 | COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED | — |
| Aug 10, 2024 | NA85 | NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED | — |
| Aug 10, 2024 | C15P | REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. | — |
| Aug 10, 2024 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 25, 2024 | E815 | TEAS SECTION 8 & 15 RECEIVED | — |
| Jul 25, 2022 | REM1 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED | — |
| Dec 18, 2018 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Jul 25, 2017 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 21, 2017 | SUNA | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | — |
| Jun 20, 2017 | CNPR | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | — |
| Jun 6, 2017 | SUPC | STATEMENT OF USE PROCESSING COMPLETE | — |
| Jun 6, 2017 | AITU | CASE ASSIGNED TO INTENT TO USE PARALEGAL | — |
| May 10, 2017 | IUAF | USE AMENDMENT FILED | — |
| May 10, 2017 | EISU | TEAS STATEMENT OF USE RECEIVED | The applicant filed a Statement of Use with specimens showing the mark in actual commerce. The USPTO will review the filing for compliance. If accepted, the mark can proceed to registration; if deficient, the USPTO may issue a requirement or office action. |
| Nov 29, 2016 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Oct 4, 2016 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 4, 2016 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 14, 2016 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 29, 2016 | PREV | LAW OFFICE PUBLICATION REVIEW COMPLETED | — |
| Aug 23, 2016 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 18, 2016 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Aug 17, 2016 | ALIE | ASSIGNED TO LIE | — |
| Aug 17, 2016 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Aug 17, 2016 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Aug 17, 2016 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| May 9, 2016 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| May 9, 2016 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| May 9, 2016 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 16, 2016 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 15, 2016 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 15, 2016 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 20, 2015 | GPRN | NOTIFICATION OF PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 20, 2015 | GPRA | PRIORITY ACTION E-MAILED | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 20, 2015 | CPRA | PRIORITY ACTION WRITTEN | A priority action is a type of Office Action the USPTO treats as time-sensitive. It usually means the examining attorney needs a specific response or amendment quickly — often relating to a foreign priority claim or a formal requirement. Respond within the stated deadline. |
| Oct 12, 2015 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 8, 2015 | MPMK | NOTICE OF PSEUDO MARK E-MAILED | — |
| Jul 7, 2015 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 4, 2015 | NWAP | NEW APPLICATION ENTERED | — |